159 related articles for article (PubMed ID: 5358212)
21. Clinical study of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in carcinoma of the lung.
Mizgerd JB; Amick RM; Hilal HM; Patno ME
Cancer Chemother Rep; 1971 Feb; 55(1):83-6. PubMed ID: 5121654
[No Abstract] [Full Text] [Related]
22. Intermittent treatment of metastatic malignant melanoma with high-dose 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
Cowan DH; Bergsagel DE
Cancer Chemother Rep; 1971 Apr; 55(2):175-81. PubMed ID: 5118686
[No Abstract] [Full Text] [Related]
23. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.
Einhorn LH; McBride CM; Luce JK; Caoili E; Gottlieb JA
Cancer; 1973 Oct; 32(4):749-55. PubMed ID: 4751911
[No Abstract] [Full Text] [Related]
24. Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
Gams RA; Carpenter JT
Cancer Chemother Rep; 1974; 58(5 Pt 1):753-4. PubMed ID: 4214608
[No Abstract] [Full Text] [Related]
25. New approaches in administration of anticancer drugs.
Rall DP
Cancer Res; 1969 Dec; 29(12):2471-4. PubMed ID: 5369694
[No Abstract] [Full Text] [Related]
26. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
Kline I; Woodman RJ; Gang M; Venditti JM
Cancer Chemother Rep; 1971 Feb; 55(1):9-28. PubMed ID: 5121657
[No Abstract] [Full Text] [Related]
27. [Effect of various chemotherapeutic agents on the synthesis and distribution of DNA in human strains of kidney and lung cancer, melanoma and Ewing's sarcoma transplanted to athymic mice].
Revazova ES; Petrova AS; Iudicheva TV; Zubrikhina TN
Biull Eksp Biol Med; 1981 Oct; 91(10):471-3. PubMed ID: 7317610
[No Abstract] [Full Text] [Related]
28. Adaptation of a colorimetric determination of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (NSC-45388) and 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) to blood.
Field RB; Hoffman G; Waravdekar VS; Kline I
Cancer Chemother Rep; 1969 Jun; 53(3):199-202. PubMed ID: 4980814
[No Abstract] [Full Text] [Related]
29. Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide.
Gottlieb JA; Baker LH; Quagliana JM; Luce JK; Whitecar JP; Sinkovics JG; Rivkin SE; Brownlee R; Frei E
Cancer; 1972 Dec; 30(6):1632-8. PubMed ID: 4663966
[No Abstract] [Full Text] [Related]
30. Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Hill GJ; Larsen RR
Oncology; 1972; 26(2):206-22. PubMed ID: 4626137
[No Abstract] [Full Text] [Related]
31. [Adjuvant chemotherapy for some common malignant tumors].
Wu YF
Zhonghua Yi Xue Za Zhi; 1983 Oct; 63(10):641-4. PubMed ID: 6426727
[No Abstract] [Full Text] [Related]
32. Chemotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and dactinomycin.
Gerner RE; Moore GE; Didolkar MS
Cancer; 1973 Oct; 32(4):756-60. PubMed ID: 4751912
[No Abstract] [Full Text] [Related]
33. What can the clinician expect from the chemotherapy of tumors of the breast, colon, and lung?
Panettiere FJ
J Ark Med Soc; 1980 Oct; 77(5):199-203. PubMed ID: 6448247
[No Abstract] [Full Text] [Related]
34. Clinical cancer chemotherapy aimed at potential cell regulators.
Knock FE; Galt RM; Renaud OV; Oester YT
Arch Surg; 1970 Feb; 100(2):167-72. PubMed ID: 5460788
[No Abstract] [Full Text] [Related]
35. Elevated inary excretion of 4-aminoimidazole-5-carboxamide in patients after intravenous injection of 4-(3,3-dimethyl-1-triazeno)imidazole-5-carboxamide.
Housholder GE; Loo TL
Life Sci; 1969 May; 8(9):533-6. PubMed ID: 5791705
[No Abstract] [Full Text] [Related]
36. 5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy.
Komp DM; Land VJ; Nitschke R; Cangir A; Dyment P
Cancer Chemother Rep; 1975; 59(2 Pt 1):371-6. PubMed ID: 1097094
[No Abstract] [Full Text] [Related]
37. Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
Vogel CL; Primack A; Owor R; Kyalwazi SK
Cancer Chemother Rep; 1973 Feb; 57(1):65-71. PubMed ID: 4704105
[No Abstract] [Full Text] [Related]
38. Intra-arterial therapy of melanoma with dimethyl triazeno imidazole carboxamide (NSC-45388).
Savlov ED; Hall TC; Oberfield RA
Cancer; 1971 Nov; 28(5):1161-4. PubMed ID: 5166498
[No Abstract] [Full Text] [Related]
39. Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
Falkson G; Van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Oct; 56(5):671-7. PubMed ID: 4569061
[No Abstract] [Full Text] [Related]
40. Response of localized melanoma to intra-arterial dimethyl triazeno imidazole carboxamide: a case report.
Savlov ED; Hall TC
J Surg Oncol; 1970; 2(4):341-7. PubMed ID: 5520849
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
